|
Patent landscape, scope, and claims: |
United States Drug Patent 9,271,990: Scope, Claims, and Landscape Analysis
United States Patent 9,271,990, titled "Combinations of Ridaforolimus with other therapeutic agents," was issued on March 1, 2016, to ARIAD Pharmaceuticals, Inc. The patent covers specific combination therapies involving ridaforolimus, an mTOR inhibitor, with other pharmaceutical agents for treating various cancers.
What is the Core Invention of Patent 9,271,990?
The central innovation protected by Patent 9,271,990 is the synergistic effect achieved by co-administering ridaforolimus with certain other drugs. This combination is intended to enhance therapeutic efficacy beyond what is achievable with monotherapy. The patent claims focus on specific drug combinations and methods of treatment utilizing these combinations.
What are the Key Claims of Patent 9,271,990?
Patent 9,271,990 contains multiple claims, with the independent claims defining the broadest scope of protection.
Claim 1: Combination Therapy
Independent Claim 1 describes a pharmaceutical composition comprising:
- Ridaforolimus.
- A second therapeutic agent selected from a defined list, including but not limited to other mTOR inhibitors, chemotherapy agents, hormonal therapies, and targeted therapies.
- A pharmaceutically acceptable carrier.
The claim further specifies that the composition is for use in treating a proliferative disorder.
Claim 2: Method of Treatment
Independent Claim 2 outlines a method of treating a proliferative disorder in a subject, comprising administering to the subject an effective amount of:
- Ridaforolimus.
- A second therapeutic agent, as defined in Claim 1.
The method is directed to achieving a therapeutic effect, such as inhibiting tumor growth or inducing tumor cell death.
Dependent Claims: Specifics and Administration
Dependent claims elaborate on the independent claims by specifying:
- Particular classes or specific examples of the second therapeutic agent (e.g., everolimus, temsirolimus, docetaxel, paclitaxel, gefitinib, erlotinib).
- Specific proliferative disorders (e.g., breast cancer, lung cancer, prostate cancer, renal cell carcinoma, melanoma, leukemia).
- Dosage ranges and administration schedules for both ridaforolimus and the second therapeutic agent.
- The method of administration (e.g., oral, intravenous).
- The synergistic nature of the combination, demonstrating a greater than additive therapeutic effect.
The patent defines "proliferative disorder" broadly, encompassing conditions characterized by abnormal cell proliferation.
What is the Patent Landscape for Ridaforolimus and mTOR Inhibitors?
The patent landscape for ridaforolimus and related mTOR inhibitors is complex, reflecting significant investment and competition in the field of cancer therapeutics. ARIAD Pharmaceuticals, Inc. has historically been a major player in this space.
Key Patent Holders and Their Focus
- ARIAD Pharmaceuticals, Inc.: Holds foundational patents for ridaforolimus (also known as AP23573) and its therapeutic applications, including combination therapies. Patent 9,271,990 is an example of their strategy to broaden protection around the drug by covering specific combination uses. Other patents may cover the compound itself, manufacturing processes, and distinct therapeutic indications.
- Novartis AG: A significant competitor in the mTOR inhibitor space, with drugs like everolimus (Afinitor) and temsirolimus (Torisel). Novartis holds numerous patents covering these compounds, their formulations, and uses in various cancer types, often involving combination therapies.
- Pfizer Inc.: Holds patents related to other mTOR inhibitors and their use in oncology.
- Other Biotech and Pharmaceutical Companies: Numerous smaller and larger entities hold patents for novel mTOR modulators, dual PI3K/mTOR inhibitors, and specific combination therapies targeting particular cancer pathways.
Trends in mTOR Inhibitor Patenting
- Combination Therapies: A substantial portion of recent patent filings focuses on synergistic combinations with other targeted therapies (e.g., HER2 inhibitors, ALK inhibitors), immunotherapies (e.g., checkpoint inhibitors), and chemotherapy. This reflects the understanding that complex diseases like cancer require multi-pronged treatment strategies.
- New Formulations and Delivery Systems: Patents are also emerging for improved formulations of existing mTOR inhibitors to enhance bioavailability, reduce toxicity, or enable novel delivery methods.
- Specific Cancer Indications: Patent protection is increasingly being sought for the use of mTOR inhibitors in narrower, well-defined patient populations or specific subtypes of cancer, often based on biomarker identification.
- Dual Inhibitors: Development and patenting of dual inhibitors targeting mTOR and other key signaling pathways (e.g., PI3K, DNA-PK) is an active area.
How Does Patent 9,271,990 Fit into the Broader Intellectual Property Strategy?
Patent 9,271,990 represents a strategy to extend the commercial exclusivity of ridaforolimus beyond its basic compound patent. By claiming specific combination therapies, ARIAD aims to:
- Block Competitors: Prevent other companies from marketing combinations that include ridaforolimus with the patented second agents for the claimed uses.
- Secure Market Position: Create a more robust intellectual property portfolio that deters generic entry and supports continued market exclusivity.
- Enable Licensing Opportunities: Provide a basis for licensing agreements with other pharmaceutical companies looking to develop or market these specific combination treatments.
The effective lifespan of a patent is critical. For Patent 9,271,990, issued in 2016, its term would extend for 20 years from its filing date, subject to any patent term extensions or adjustments.
What are the Implications for R&D and Investment Decisions?
The scope and claims of Patent 9,271,990 have direct implications for companies involved in oncology R&D or investment.
R&D Considerations
- Freedom to Operate (FTO): Companies developing new cancer therapies, particularly those involving mTOR inhibition or combination strategies with agents listed in the patent, must conduct thorough FTO analysis. This involves assessing whether their proposed products or methods infringe on existing patents like 9,271,990.
- Drug Discovery and Development: For those aiming to develop ridaforolimus-based therapies, understanding the specific combinations covered is crucial. Alternative combinations not explicitly claimed, or novel ridaforolimus analogs with different patent protection, may be viable development paths.
- Biomarker Development: Identifying patient populations that would specifically benefit from the synergistic effects described in the patent can inform clinical trial design and potential sub-indication targeting.
Investment Considerations
- Competitive Landscape Assessment: Investors must evaluate the strength and breadth of the patent portfolio surrounding key oncology drugs. Patent 9,271,990 contributes to ARIAD's (or its successors') IP strength for ridaforolimus.
- Pipeline Analysis: When evaluating companies with mTOR inhibitors or combination therapy pipelines, assessing the patent status of their lead candidates and their competitive positioning relative to patents like 9,271,990 is vital.
- Generic Entry Risk: The existence of broad combination patents can delay or prevent the market entry of generic versions of the monotherapy drug if the generic is also claimed as part of a combination. However, generic manufacturers often challenge the validity or scope of such patents.
- M&A Due Diligence: For mergers and acquisitions involving companies with relevant oncology assets, a detailed review of the patent landscape, including patents like 9,271,990, is a standard due diligence requirement.
Key Takeaways
- United States Patent 9,271,990 protects specific combination therapies of ridaforolimus with other therapeutic agents for treating proliferative disorders.
- The patent's claims cover pharmaceutical compositions and methods of treatment, aiming to leverage synergistic therapeutic effects.
- The patent landscape for mTOR inhibitors is characterized by extensive patenting of combination therapies, new formulations, and specific cancer indications by multiple major pharmaceutical companies.
- Patent 9,271,990 is a strategic asset designed to extend ridaforolimus's market exclusivity and deter competitor activity.
- For R&D and investment, this patent necessitates rigorous freedom-to-operate analysis, strategic pipeline development, and a thorough understanding of the competitive intellectual property environment.
FAQs
-
What is the primary mechanism of action for ridaforolimus?
Ridaforolimus is an mTOR inhibitor. It targets the mammalian target of rapamycin (mTOR) kinase, a key regulator of cell growth, proliferation, motility, survival, protein synthesis, and transcription. By inhibiting mTOR, ridaforolimus disrupts these processes, particularly in cancer cells that rely on mTOR signaling for their growth and survival.
-
Can other companies develop ridaforolimus in combination with drugs not listed in Patent 9,271,990?
The patent claims a specific list of second therapeutic agents. Companies can potentially develop ridaforolimus in combination with agents not listed in Claim 1, provided those combinations do not infringe on other existing patents covering ridaforolimus or the other agents, and assuming they are not otherwise blocked by patent claims or regulatory exclusivities. A thorough freedom-to-operate search is required for any new combination.
-
What is the difference between a compound patent and a method-of-use patent like 9,271,990?
A compound patent protects the chemical entity itself, regardless of its use. A method-of-use patent, like 9,271,990, protects a specific application or therapy involving a known compound. This patent does not claim ridaforolimus itself, but rather its use in specific combinations for treating diseases.
-
How long is United States Patent 9,271,990 expected to be in effect?
United States patents generally have a term of 20 years from the filing date. For Patent 9,271,990, filed on November 10, 2004, and issued on March 1, 2016, its potential term would extend to November 10, 2024, subject to any extensions or adjustments granted by the USPTO.
-
What is the significance of "synergistic effect" in the context of Patent 9,271,990?
A synergistic effect means that the combined effect of ridaforolimus and the second therapeutic agent is greater than the sum of their individual effects when administered separately. This implies that the combination can achieve superior therapeutic outcomes, such as increased tumor shrinkage or prolonged survival, with potentially lower doses or reduced toxicity compared to using each drug alone.
Citations
[1] ARIAD Pharmaceuticals, Inc. (2016). Combinations of Ridaforolimus with other therapeutic agents. U.S. Patent 9,271,990. Washington, D.C.: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
